Three major areas are emphasized for a study of drug excretion in breast milk: maternal drug disposition, breast milk pharmacokinetics and neonatal drug elimination. The first two impact on drug dose to infant whereas the last area is crucial to drug accumulation in the infant. Pitfalls in assessment of the drug concentration in milk to plasma (M/P) ratio are illustrated to expose errors in drug dose in milk estimates. Predictions about drug dose in milk must be confirmed by sampling of both milk and infant plasma for drug concentration. Principles for drug excretion in breast milk can be used as guidelines for excretion of a growing number of toxic agents.
INTRODUCTION
Too little information is available on drug excretion in human breast milk. Caveats or proscriptions were placed on 13% of drugs in the Physicians Desk Reference (PDR) of 1973 (Table 1) , but many more drugs lacked information sufficient to make recommendations to breast feeding women. This situation has not changed much in the last decade as is apparent from the number of drugs studied recently (Table 2) . It is distressing to note how few women have been studied in reports summarized in the Table. It is unlikely that this paucity of individuals would be admissable in a Phase I drug evaluation report for submission to the Food and Drug Administration (FDA) in the United States. Why do we accept a lack of pharmacologic information on the breast feeding woman and her infant? From: Wilson, 1975 . Source Evaluated: Physician's Desk Reference 1973 (n = 2000 medicines). Restriction based on a statement of prohibition or caution or (for children) no dose information given. * Most medicines had no information about suitability of use in these persons. Findlay, 1981 Bitzen, 1981 Berlin, 1980 Findlay, 1981 Pittman, 1980 Kampmann, 1980 Stec, 1980 Jarboe, 1981 Moore, 1979 Erickson, 1981 Nau, 1981 Steen, 1982 Devlin, 1981 Devlin, 1981 Reinhardt, 1982 Chrombio, 1982 Orme, 1977 Swiet, 1977 Ferguson, 1976 Study defined as one which involved a pharmacokinetic analysis of data from multiple persons (mothers and/or infants).
The breast feeding woman and her infant are the most suitable ones for a study of drug excretion in breast milk. Animal studies are useful as a first approach to many questions, but animal results are too often qualified for application to man. Ethical and technological advances allow the human subject to serve herself and fellow humans by participation in studies of drug excretion in breast milk. Ancedotal evidence has often guided decisions about breast feeding by women who are receiving medicines. Such guidelines can be erroneous and misleading. We must now press for well controlled studies of drug excretion in breast milk when it is safe and ethically feasible to do such studies. How long will we tolerate insufficient answers on this important matter? How long will we allow a lack of knowledge to dictate breast feeding practices to thousands of women who need drugs for their own health?
IMPORTANT QUESTIONS WHICH SHOULD BE ASKED
The clinical imperative of having more information is underscored by certain questions encountered frequently concerning drugs in breast milk. Does the drug get into milk? If so, then how much of a drug gets into milk? Will the drug in milk harm the baby? Should nursing be discontinued? The important 192 global question is: how much drug is administered to the infant via breast milk?
Appropriate answers to these and other questions must come from studies of drug disposition in the mother and her infant when ethical and medical conditions permit. General areas covered by such studies are shown in Table  3 . The summary item 4 emphasizes that drug dosing of infant via breast milk A description of drug disposition in the mother as it relates to presentation of a drug to the breast for secretion in milk.
Mammary pharmacokinetics.
A description of the sojourn of a drug in milk in relation to the formation and excretion of milk.
Developmental pharmacokinetics.
A description of drug absorption and disposition (metabolism, excretion, distribution) of a drug delivered in milk to the child. 4. Interrelationship of items 1 and 2 and 3 provides information on how much drug gets to the infant via breast milk and how much drug will accumulate in the infant to exert a pharmacologic or toxic action.
is indirect since it is a function of maternal and breast disposition of the drug.
To describe this disposition with high predictability for dose estimates to the infant, a pharmacokinetic approach after single dose and at steady state dosing is necessary. A useful kinetic model is shown in Figure 1 which presents the breast milk as a deep compartment for drug accumulation prior to delivery to infant. For some drugs their disposition may closely fit a two compartment open model where milk is the more accessible second compartment. Various pharmacokinetic models are described in our previous work (Wilson et al., 1981) . The amount of drug gaining access to the infant is a direct function of dose and resultant maternal plasma concentration. This latter obeys the Wagner equation for average steady state if the elimination is by first order kinetics (Wagner et al., 1965) . The most important variable is the elimination rate constant. Interindividual variation in this rate constant is recognized and knowledge about it and other disposition parameters during the latter part of pregnancy and early puerperium are emerging ( Figure 2 ). Such parameters may change the maternal plasma drug concentration with an expected concurrent change in the amount of drug delivered to the breast. An increase in drug concentration after birth would be expected to deliver more drug to the breast and hence to milk if other factors such as drug protein binding did not change. For a highly protein bound drug a decrease in binding would produce a higher free drug concentration available for diffusion into breast milk. Thus, in addition to dose, maternal drug disposition influences the amount of drug in milk.
More is known about mammary pharmacokinetics with regard to physiology and physicochemical nature of drugs in milk. Milk is secreted into the alveolar lumen of each lobulus which empties into lactiferous ducts and finally collects in lactiferous sinuses prior to their being emptied in the process of infant sucking. Entry of most drugs into milk is by passive diffusion through the alveolar cell ( Figure 3 ). Once in milk the drug can be associated with three constituents of milk (Table 4 ). More is known about drug in aqueous media where free drug concentration is governed by ion trapping. The pH of milk changes with regard to fore and hind milk ( Figure 4 ). Weak acids have a milk to plasma (M/P) ratio of generally <1 whereas weak bases are trapped in milk with a M/P > 1. This occurs because milk is usually acidic with regard to plasma . Figure 3 . Transit path of a drug from blood to milk (from Wilson et al., 1981, p 22 ). Ion trapping is a function of pH differential as well as drug pKa as shown in Table 5 . The importance of fat rich hind milk (Figure 4 ) for enhanced excretion of fat soluble drugs has not been systematically studied but is expected to deliver more of such drugs to the infant. The impact of mammary physiology and physical nature of drugs is appreciated from studies of the M/P ratio. After a single dose the M/P ratio for acetaminophen (a weak acid) was about 0.85 in accordance with that predicted ( Figure  5 ). For Nadolol (a weak base) the single dose M/P ratio was <1 but conformed to 195 For each respective medium the mechanism of exit from the alveolar cell into milk is apocrine secretion, reverse pinocytosis and diffusion (or active transport(?)). Predominate residence of drug in milk may be determined in luminal media.
From: J. T. Wilson, 1983 . Weak acids in Plasma e.g., Sulfamerazine (pKa 7.06) MIP= 0.5 that expected of > 1 when steady state levels were assessed ( Figure 6 ). These Nadolol data illustrate a major pitfall in use of simple single dose studies to determine M/P ratios for drugs given chronically to achieve steady state plasma concentrations in the mother. Namely, the M/P ratio reversed at steady state conditions as compared to that after a single dose. It was also higher (>>1) at steady state than during later parts of the plasma decay profile. This indicated a more rapid fall in milk with respect to plasma. For this drug, the M/P ratio 196 used for estimates of drug excretion with respect to plasma concentration must be based on the duration of drug dosing. Major errors could be made if single dose data were used for patients receiving chronic doses. For many other drugs (e.g. digoxin and phenytoin) a more consistent M/P ratio was found during the dosing interval (Steen et al., 1982 , Reinhardt et al., 1982 .
The calculations of drug dose given via breast milk to the infant are described in Table 6 . It is apparent that an accurate M/P ratio is needed for these calculations. While the mother's plasma drug concentration can be measured prior to a feeding, the translation of this into a drug concentration in milk requires a M/ P ratio applicable to both the drug and to chronicity of dosing. The derived drug dose to infant is often shown as percent of maternal dose (Table 7) . For many drugs this is less than 1% and, as such, delivers a nontherapeutic amount of drug to the infant in a single dose. Drug accumulation with repeated dosing, however, may lead to higher levels in the infant (see below). Additionally, interindividual variation for dose of drug in milk has been found among breast feeding women as illustrated by antipyrine concentrations (Table 8 ). For those drugs given chronically or repeatedly, it is preferable to assess the amount in milk by use of maternal plasma and milk concentrations and also the M/P ratio, and then the drug concentration in infant plasma is monitored at the time of expected steady state (i.e. at about 5 x tVz of drug in the infant). Such monitor- ing can confirm or not the predictions about dose of drug in milk and substantiate risk -benefit assessments for the child.
Drug disposition in the infant must be addressed by a comprehensive approach to drug excretion in breast milk. The drug dose in milk may be a fraction of the maternal dose but, aside from the difference between maternal and infant weight, there may be a marked difference in drug clearance in the infant such that the drug accumulates to higher than expected levels. For example, Table 9 highlights differences in plasma tlf2 for some commonly used drugs in neonates. These neonate to adult differences in plasma drug tlf2 are 10-20 fold in some cases. While some (Stec et al., 1980; Nau et al., 1981) have predicted infant plasma levels based on drug dose in milk and the infant's drug clearance, few studies have undertaken monitoring of breast milk and plasma from infant and mother to confirm predictions. A recent study showed that plasma phenytoin levels of breast fed infants were much below the therapeutic range (Table 10) . This was also shown for the ethosuximide (Rane et al., 1981) . The chloramphenicol associated grey baby syndrome, however, reminds us that immature drug clearance can lead to unexpected and toxic drug levels in an infant.
While this discussion has focused on drugs in breast milk, exposure of the lactating mother to environmental toxins places her and her infant potentially at risk. The maternal dose of a drug is often known, but for toxins the exposure 198 is difficult to quantitate. However, many such substances have been detected Steen et al., 1982. in maternal plasma and milk. A list of environmental toxins found in milk is seen in Table 11 . Their pharmacokinetic behaviour should follow principles applicable to drugs in general with perhaps more emphasis placed on the fat content of hindmilk for many of these highly lipid soluble agents. As reviewed in our previous work (B. Manno, 1981) , a massive localized exposure to methylmercury resulted in prolonged excretion of the toxin in milk. For this and other agents (Poland and Cohen, 1980) the long term consequences to infants remain unknown. One consequence predictable from animal studies (Fouts and Hart, 1965) is that of enzyme induction to increase the clearance of drugs. This may impact on the infants exposed to environmental agents in milk and hence render some drugs ineffective for treatment of disease in such infants.
In summary, a meagre data base on pharmacokinetic behavior of drugs in breast milk does allow some helpful guidelines (Table 12 ). The least amount of drug should be found in milk just before dosing and this is exaggerated for a drug with a short tl/2. A higher M/P ratio as found with a basic drug presupposes a larger amount of drug in acidic milk. Consumption of large amounts of breast milk delivers a larger drug dose. Unexpected drug accumulation may occur if 199 
Maternal
Higher dose and rapid absorption ~ higher cone. Short drug tlfz: Feed just before a dose.
Mammary
High MIP ratio ~ higher cone. TmaxM > TmaxP ~longer duration. tlfzM > t 1 hP ~ longer duration.
Basic drug ~ higher cone. than acidic.
Neonatal
Larger feeding~ higher amount (dose). Developmentally delayed renal or hepatic function ~ drug accumulation.
the drug elimination pathways of the infant are very immature or compromised. While drug excretion in breast milk does follow some general rules and allow predictions, the observed interindividual variation among women and the M/P ratio differences found for single and chronic dosing require that each drug be studied with an appropriate pharmacokinetic design in enough women to provide values applicable to the general population. Use of such values for predictions in the individual patient can be confirmed by plasma drug level monitoring of the infant suckling a mother who receives chronic pharmacotherapy. Similar principles can be applied to populations exposed to toxins so that both immediate and protracted risk can be related to dose in milk and chronicity of exposure.
